Next Jump

Dragonfly Therapeutics, located in Cambridge, MA, is a clinical-stage biotech company dedicated to transforming the treatment of various diseases through innovative natural killer cell-based therapies. With proprietary platforms including TriNKETs and CYTOKINEs, Dragonfly has developed a robust pipeline with a focus on autoimmune diseases, oncology, and neuro-inflammation, targeting significant patient needs. The company has formed strategic collaborations with industry leaders like AbbVie, BMS, Gilead, and Merck, leading to the advancement of 11 drug candidates. Dragonfly aims to continuously grow its pipeline, augmenting its research in a range of therapeutic areas, including fibrotic diseases and infectious diseases, to ensure improved patient outcomes. Generated from the website

LiquiGlide, based in Cambridge, MA, is a pioneering surface engineering technology company that specializes in creating durable, slippery surfaces. Their innovative coatings consist of a textured solid material that traps a liquid lubricant through capillary and intermolecular forces, resulting in self-lubricating surfaces that are custom designed to adhere to a variety of materials and environmental conditions. Utilizing a proprietary algorithm and leveraging chemical affinity and capillarity, LiquiGlide's technology sets itself apart from conventional superhydrophobic surfaces by offering long-lasting slipperiness that can be tailored for food safety, industrial environments, and other specific applications. With a robust global IP portfolio and a focus on innovation, LiquiGlide is at the forefront of building a frictionless future.Generated from the website

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website